Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niren K Shah

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Review of Cardiovascular Therapy|November 9, 2011
Less RAAS is more, or notNiren K Shah, Rushab Choksi, Benjamin J Epstein
Expert Review of Cardiovascular Therapy|August 17, 2012
The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyondBenjamin J Epstein, Paul T Leonard, Niren K Shah
Therapeutic Advances in Cardiovascular Disease|August 16, 2013
Management of hypertension with fixed-dose triple-combination treatmentsBenjamin J Epstein, Niren K Shah, Nancy L Borja-Hart
Pharmacotherapy|March 7, 2012
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitusNiren K Shah, Wasim E Deeb, Rushab Choksi, et al.
The Annals of Pharmacotherapy|February 4, 2010
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonistShawn D Anderson, Niren K Shah, Juwon Yim, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 7, 2011
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study)Niren K Shah, Steven M Smith, Wilmer W Nichols, et al.
Journal of the American Society of Hypertension : JASH|March 18, 2014
Baseline predictors of central aortic blood pressure: a PEAR substudyRebecca F Rosenwasser, Niren K Shah, Steven M Smith, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Review of Cardiovascular Therapy|November 9, 2011
Less RAAS is more, or notNiren K Shah, Rushab Choksi, Benjamin J Epstein
Expert Review of Cardiovascular Therapy|August 17, 2012
The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyondBenjamin J Epstein, Paul T Leonard, Niren K Shah
Therapeutic Advances in Cardiovascular Disease|August 16, 2013
Management of hypertension with fixed-dose triple-combination treatmentsBenjamin J Epstein, Niren K Shah, Nancy L Borja-Hart
Pharmacotherapy|March 7, 2012
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitusNiren K Shah, Wasim E Deeb, Rushab Choksi, et al.
The Annals of Pharmacotherapy|February 4, 2010
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonistShawn D Anderson, Niren K Shah, Juwon Yim, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 7, 2011
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study)Niren K Shah, Steven M Smith, Wilmer W Nichols, et al.
Journal of the American Society of Hypertension : JASH|March 18, 2014
Baseline predictors of central aortic blood pressure: a PEAR substudyRebecca F Rosenwasser, Niren K Shah, Steven M Smith, et al.
Pageof 1